title: Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.
authors.affiliation: Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Masago
authors.forename: Masako
authors.initials: M
authors.lastname: Miura
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Toyama
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Togashi
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mishima
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D004252:DNA Mutational Analysis; D004815:Epidermal Growth Factor / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005091:Exons; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D016133:Polymerase Chain Reaction; D011799:Quinazolines / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride